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Abstract 
Objectives. To date, no second-line chemotherapy regimen for esophageal squamous cell 
carcinoma (SCC) has been established. This clinical trial aimed to assess the optimum 
dose of docetaxel plus nedaplatin (cis-diammine-glycolate platinum) as second-line 
chemotherapy. 
Methods. Patients with metastatic or recurrent esophageal SCC after treatment with 
cisplatin plus 5-fluorouracil received docetaxel (50 or 60 mg/m2) plus nedaplatin (70 
mg/m2) on day 1 every 4 weeks. The recommended dose was based on dose-limiting 
toxicities (DLTs) defined during the first cycle. 
Results. From February 2009 to November 2011, nine patients were enrolled in the 
study. Their median age was 62 years (range 58–72 years). Six patients had undergone 
radiotherapy and four had undergone surgical resection of primary lesions. DLTs were 
observed in two patients at dose level 1 (60 mg/m2 docetaxel, 70 mg/m2 nedaplatin) but 
not at dose level 0 (50 mg/m2 docetaxel, 70 mg/m2 nedaplatin). Thus, the maximum 
tolerated dose was established at dose level 1. No severe nonhematological toxicity was 
observed. No patient achieved complete response, but two (22%; 95% confidence interval, 
0%–49%) achieved partial response and three had stable disease. Median 
progression-free and overall survival times were 2.1 months and 9.5 months, 
respectively. 
Conclusions. Docetaxel plus nedaplatin chemotherapy appears to be a safe and feasible 
second-line regimen for the treatment of esophageal SCC. We recommend the 
administration of 50 mg/m2 docetaxel (day 1) plus 70 mg/m2 nedaplatin (day 1) every 4 
weeks in a phase II study. 
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1.  Introduction 
Esophageal squamous cell carcinoma (SCC) is one of the most aggressive cancers. It is 
well known for its aggressive nature, which is manifested as invasiveness and 
metastasis to regional lymph nodes and distant organs. Chemotherapy can induce a 
response in approximately 30%–40% of patients that are inoperable or those that show 
postoperative relapse; however, the survival of patients with advanced esophageal SCC 
is poor (median survival time 7–8 months).1,2 SCC is the most common histological type 
of esophageal cancer in Japan. A combination of cisplatin and continuous-infusion 
5-fluorouracil is regarded as the standard regimen for esophageal SCC. A Japanese 
study reported an overall response rate of 33% and median survival time of 7.5 months.2 
Chemoradiotherapy with 5-fluorouracil plus cisplatin resulted in a complete response in 
33% of patients with locally advanced disease3 and 70% of patients with resectable 
disease.4 However, no second-line chemotherapy regimen for esophageal SCC has been 
established to date. The few trials of second-line treatments that have been performed 
have reported poor results,5 and there is an urgent need for the development of a 
suitable second-line regimen. 
Nedaplatin (cis-diammine-glycolate platinum; Shionogi Pharma, Osaka, Japan) is a 
second-generation platinum derivative developed in Japan. It has been shown to have a 
high response rate in various cancers, particularly in esophageal SCC.6 A 
cisplatin-resistant human leukemia cell line, which had 10-fold resistance to cisplatin, 
was as sensitive to nedaplatin (1.0-fold) as the parent cells. 7 The results indicate that 
nedaplatin may be used to overcome the drug resistance developed in the patients after 
treatment with cisplatin. Docetaxel (Sanofi-Aventis, Paris, France) has also been shown 
to have single-agent activity in patients with metastatic or recurrent esophageal SCC.8 
Docetaxel stabilizes the microtubules and inhibits mitosis, whereas nedaplatin 
primarily acts as an alkylating agent. The mechanisms of action of these two drugs are 
thus different. Therefore, a regimen of docetaxel plus nedaplatin would be expected to 
result in additive antitumor effects with nonoverlapping toxicity profiles. To assess the 
recommended dose of docetaxel plus nedaplatin to be used in a phase II study and to 
determine the toxicity and efficacy of the regimen, we conducted a phase I study of 
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docetaxel plus nedaplatin in patients with metastatic or recurrent esophageal SCC after 
cisplatin plus 5-fluorouracil treatment. 
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2.  Materials and Methods 
2.1. Eligibility criteria 
Patients with metastatic or recurrent esophageal SCC who had previously been 
treated with cisplatin plus 5-fluorouracil were enrolled in the study. The eligibility 
criteria were as follows: (a) histologically confirmed esophageal SCC; (b) age 20–75 
years, (c) Eastern Clinical Oncology Group performance status score ≤2; (d) life 
expectancy of at least 8 weeks; (e) provision of written informed consent; (f) adequate 
bone marrow function (white blood cell count ≥3000/mm3, platelet count ≥100 000/mm3); 
(g) adequate hepatic function (total serum bilirubin level ≤1.5 mg/dl, aspartate 
aminotransferase and alanine aminotransferase levels less than or equal to twice the 
upper limit of the normal ranges); and (h) adequate renal function (serum creatinine 
≤1.5 mg/dl). Exclusion criteria included concomitant uncontrolled diabetes mellitus, 
hypertension, severe heart disease, active infection, active double cancer, massive 
ascites, massive pleural effusion, massive pericardial effusion, active gastrointestinal 
tract bleeding, possible pregnancy, brain metastases with any symptoms, severe 
psychological disease, and tracheoesophageal fistula formation.  
 
2.2. Treatment plan 
On day 1, an intravenous (i.v.) infusion of a mixture of 5-hydroxytryptamine-3 
receptor antagonist and dexamethasone (8 mg/kg body weight) diluted with 100 ml of 
normal saline was administered over 30 min. Subsequently, docetaxel was diluted with 
250 ml of normal saline and administered as a 90-min i.v. infusion. Nedaplatin was 
then diluted with 250 ml of normal saline and administered as a 90-min i.v. infusion; 
1000 ml of lactated Ringer's solution was also administered for hydration. 
 
2.3. Study design 
Five incremental dose levels were planned (Table 1). Level 1 was the starting dose 
level, but level 0 was also prepared, because level 1 could have constituted the 
maximum tolerated dose (MTD). At least three patients were treated at each dose level. 
MTD was defined as follows: if two or three of three patients experienced a dose-limiting 
toxicity (DLT), then the particular dose level was defined as MTD; if one of three 
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patients experienced DLT, three additional patients were added at the same dose level. 
If more than three of these six patients experienced DLT, then the dose level was 
defined as MTD; if fewer than three of the six patients experienced DLT, subsequent 
patients were treated at the next higher dose level. The recommended dose was defined 
as the dose just below MTD.  
The definition of DLT was as follows: (a) grade 4 neutropenia lasting for 5 or more 
days; (b) grade 4 neutropenia with fever of 38°C or more; (c) grade 3 or 4 
nonhematological toxicity except nausea, vomiting, anorexia, and transient electrolyte 
abnormalities; and (d) initiation of the second cycle of chemotherapy delayed by more 
than 8 days because of failure to meet the criteria. 
The study protocol was approved by the Institutional Review Board of Toyama 
University, Japan. All patients provided their written informed consent before entering 
the study. 
 
2.4. Evaluation of toxicity and response 
The US National Cancer Institute Common Toxicity Criteria (NCI-CTC version 3.0) 
were used to evaluate toxicity. Standard clinical measurements and radiological 
examinations were used to assess tumor response according to the Response Evaluation 
Criteria in Solid Tumors version 1.0.9 Progression-free and overall survival were 
analyzed using the Kaplan–Meier method. Survival was measured from the date of 
registration to the date of death or the last confirmed date of survival. Survival time 
was censored at the last confirmation date if the patient remained alive. 
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3.  Results 
3.1. Patient characteristics 
In total, nine patients were enrolled in the trial between February 2009 and 
November 2011 (Table 2). These included eight males and one female and their median 
age was 62 years (range, 58–72 years). Two, six, and one patient had a performance 
status score of 0, 1, and 2, respectively. All patients had histologically confirmed 
esophageal SCC and all had previously been treated with cisplatin plus 5-fluorouracil. 
Six patients had undergone radiotherapy and four had undergone surgical resection of 
the primary lesions. Metastatic lesions were detected in the lymph nodes (n = 9), lungs 
(n = 5), liver (n = 3), and bone (n = 3). All patients failed prior therapy because of disease 
progression. 
 
3.2. DLT and the recommended dose 
The number of patients who were enrolled in and experienced DLT at each dose level 
is shown in Table 1. DLT occurred in two of three patients at dose level 1 (60 mg/m2 
docetaxel, 70 mg/m2 nedaplatin). One patient had grade 4 leucopenia lasting for 7 days 
without fever, whereas in the other, initiation of the second cycle of chemotherapy was 
delayed by more than 15 days because the criteria had not been met. Three patients 
were enrolled at dose level 0 (50 mg/m2 docetaxel, 70 mg/m2 nedaplatin). No DLT was 
observed. Hence, three additional patients were enrolled, giving a total of six patients at 
this dose level. One patient experienced grade 4 neutropenia for 4 days without fever, 
whereas another had grade 3 neutropenia with fever. However, no DLT was observed at 
this dose level. Therefore, 50 mg/m2 docetaxel plus 70 mg/m2 nedaplatin was considered 
as the recommended dose. 
 
3.3. Toxicity 
The hematological and nonhematological adverse events that occurred after the first 
cycle are summarized in Tables 3. Grade 3 anemia was observed in one and two patients 
at dose levels 1 and 0, respectively. Grade 3/4 nonhematological toxicity was not 
observed at either dose level. 
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3.4. Response and survival 
No patient achieved complete response, although two patients (22%; 95% confidence 
interval, 0%–49%) achieved partial response and three patients had stable disease. 
Disease control rate (response plus stable disease) was thus 56% (95% confidence 
interval, 23%–88%). Median progression-free and overall survival times were 2.1 
months and 9.5 months, respectively (Figure 1). 
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4.  Discussion 
Our study findings suggest that a recommended dose of 50 mg/m2 docetaxel plus 70 
mg/m2 nedaplatin administered on day 1 every 4 weeks should be used in patients with 
metastatic or recurrent esophageal SCC pretreated with cisplatin plus 5-fluorouracil. 
There is no consensus as to the ideal second-line chemotherapy regimen for patients 
with esophageal SCC.5 Docetaxel monotherapy is currently the most common treatment 
option in Japan despite its overall response rate of 0%–18%.8,10,11 In a Japanese phase II 
trial, the response rate to docetaxel monotherapy (70 mg/m2 docetaxel every 3 weeks) in 
patients undergoing second-line treatment for esophageal SCC was 16%, which is 
moderate.8 Paclitaxel (Bristol-Myers Squibb, New York, USA) is a taxane, similar to 
docetaxel. A phase II trial with paclitaxel has been reported. This phase II trial showed 
promising efficacy, 44.2% of response rate, although it included not only recurrent 
patients but also progression patients to previous platinum-based chemotherapy. The 
rate of patients who failed prior platinum-based chemotherapy due to disease 
progression was 48.1%.12 
In contrast, a phase II study of nedaplatin in gastrointestinal cancer demonstrated a 
response rate of 55.6% in esophageal cancer patients with prior chemotherapy, 
including two partial response in four patients previously treated with cisplatin.13 To 
improve the outcome of chemotherapy, the administration of docetaxel in combination 
with nedaplatin has been suggested as a second-line chemotherapy regimen for patients 
with esophageal SCC. To decrease toxicity, fractionated administration of docetaxel has 
been considered. In patients with metastatic breast cancer, weekly docetaxel was 
associated with low hematological toxicity. There was no grade 4 toxicity and only 28% 
of patients had grade 3 toxicity.14 In addition, two dose-finding studies on fractionated 
docetaxel plus nedaplatin as second-line chemotherapy for esophageal SCC have been 
conducted. Yoshioka et al. recommended a dosage regimen of 30 mg/m2 docetaxel (days 
1 and 15) plus 80 mg/m2 nedaplatin (day 1) every 4 weeks; the response rate was 25%, 
and 25% of patients had grade 4 neutropenia and 17% of patients had grade 3 anorexia 
and nausea.15 Akutsu et al. recommended a dosage regimen of 50 mg/m2 docetaxel (days 
1 and 8) plus 50 mg/m2 nedaplatin (day 1) every 4 weeks; the response rate was 0% and 
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median overall survival time was 7.8 months (Table 4). Only 8% of patients had grade 4 
leukopenia and 25% of patients had grade 3 nonhematological toxicity.16  
On the other hand, fractionated administration of docetaxel has been reported to be 
associated with a higher incidence of adverse pulmonary events compared with 
conventional administration. Weekly administration of docetaxel and gemcitabine in 
patients with advanced non-small-cell lung cancer (NSCLC) was associated with a high 
incidence of severe interstitial pneumonitis.17 This study was prematurely terminated 
because 23% of patients developed fever and pulmonary dysfunction with diffuse 
interstitial pneumonitis. In addition, concurrent weekly administration of docetaxel 
with radiotherapy for NSCLC was associated with radiation pneumonitis.18 Moreover, 
fractionated administration of docetaxel has been reported to be associated with 
decreased efficacy compared with conventional administration every 3 weeks. For 
example, treatment with docetaxel every 3 weeks was associated with superior survival 
and improved response rates compared with weekly docetaxel in patients with 
metastatic hormone-refractory prostate cancer.19  
Therefore, in our study, we chose a regimen of docetaxel plus nedaplatin 
administered every 4 weeks. This is the first report, to our knowledge, of a dose-finding 
study for non-fractionated administration of docetaxel plus nedaplatin for the 
second-line treatment of metastatic esophageal SCC, although a pilot trial of 60 mg/m2 
docetaxel plus 80 mg/m2 nedaplatin administered every 4 weeks has been reported 
previously.20 In that trial, the dose of the drugs was determined according to a phase I/II 
study of first-line treatment of unresectable NSCLC, and the dose used was higher than 
our recommended dose. Their response rate was 25% and median overall survival time 
was 26 weeks (Table 4). The efficacy in their study was similar to that in our study, but 
severe neutropenia occurred in 60% of patients severe febrile neutropenia necessitating 
the use of prophylactic granulocyte colony-stimulating factor to avoid severe 
hematological toxicity occurred in 25% patients. In contrast, in our study, no febrile 
neutropenia occurred. The recommended dose for first-line chemotherapy may differ 
from that for second-line chemotherapy and also according to the type of cancer. We 
therefore conducted this phase I study to determine the recommended dose for 
esophageal SCC. 
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In conclusion, docetaxel plus nedaplatin chemotherapy administered according to our 
recommended dose appears to be a safe and feasible regimen for the second-line 
treatment of esophageal SCC. We recommend that 50 mg/m2 docetaxel (day 1) plus 70 
mg/m2 nedaplatin (day 1) be administered every 4 weeks in a phase II study. 
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Table1. Dose-escalation scheme and prevalence of dose-limiting toxicity (DLT) 
Level Docetaxel(mg/m2) Nedaplatin(mg/m2) No. of patients Patients with DLT 
0 50 70 6 0 
1 60 70 3 2 
2 60 80 Not enrolled  
3 60 90 Not enrolled  
4 70 90 Not enrolled  
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Table 2. Patient characteristics 
 Number of patients 
Sex  
    Male 8 
    Female 1 
Age (median) 62 (58-72) 
ECOG PS*  
    0 2 
    1 6 
    2 1 
Location of primary site  
    Mt 2 
    Lt 7 
Prior chemotherapy  
    Cisplatin + 5-FU 3 
    Cisplatin + 5-FU + radiation therapy 6 
Prior site  
    Operated 4 
    Remained 5 
Site of metastasis  
    Lymph nodes 9 
    Lung 5 
    Bone 3 
    Liver 3 
    Others 2 
Clinical stage (UICC+)  
    IIa 2 
    III 3 
    IVb 4 
*ECOG PS, Eastern Cooperative Oncology Performance Status  
+Union for International Cancer Control TMN classification of malignant tumor 6th Edition 
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Table 3. Adverse events after the first cycle (Common Terminology Criteria for Adverse Events ver. 3.0)  
Toxicity Dose level 1 (n=3)  Dose level 0 (n=6) 
G1 G2 G3 G4  G1 G2 G3 G4 
Hematological          
   Leucocytopenia 1 0 1 1  2 3 0 0 
   Neutropenia 0 0 1 1  0 1 1 1 
Thrombocytopenia 2 0 0 0  2 0 0 0 
   Anemia 0 2 1 0  2 1 2 0 
Nonhematological          
   Nausea/vomiting 1 0 0 0  3 0 0 0 
   Vomiting 0 0 0 0  2 0 0 0 
   Anorexia 2 0 0 0  3 2 0 0 
   Fatigue 3 0 0 0  4 0 0 0 
   Diarrhea 1 0 0 0  0 0 0 0 
   Constipation 0 0 0 0  1 0 0 0 
   Stomatitis 0 0 0 0  1 0 0 0 
   Alopecia 2 0 0 0  1 0 0 0 
   Creatinine 2 0 0 0  0 0 0 0 
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Table 4. Docetaxel plus nedaplatin treatment in patients with metastatic or recurrent esophageal 
squamous cell carcinoma pretreated with cisplatin plus 5-fluorouracil.  
Docetaxel 
every 4 weeks 
Nedaplatin 
every 4 weeks 
No. of 
Patients 
ORR 
(%) 
PFS 
(Months) 
OS 
(Months) 
Reference 
30mg/m2 
(days 1 and 15) 
80 mg/m2 
(day 1) 
6 16.6 N/S N/S Yoshioka et al.15 
50 mg/m2 
(days 1 and 8) 
50 mg/m2 
(day 1) 
12 0 2.0 7.8 Akutsu et al.16 
60 mg/m2 
(day 1) 
80 mg/m2 
(day 1) 
20 25 3.2 6.0 Nakajima et al.20 
50 mg/m2 
(day 1) 
70 mg/m2 
(day 1) 
6 33 4.4 9.5 Our study 
(Recommend dose) 
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Figure 1. Kaplan-Meier curve of nine patients.  
 
